iHuman Inc. Announces Acquisition of Businesses and Assets Related to All Knowledge and Perfect Lingo

Advise RE Outlines CPA Criteria for Cross-Border Real Estate Deals

Portugal Pathways Coordinates Cross-Border Property Purchases

401(k) and Cigna Plans Bundled in essentL PEO's National SMB Package

CPKC to maintain rail operations across Canada during IBEW strike

HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in...

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where...

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of...

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with...

GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With...

Anchor Roofing Maintains Owens Corning Platinum Preferred Contractor Status for Nebraska Homeowners

Whitlock Drivers Increase Demand for Hybrid and Diagnostic Auto Repair

Westoak Drivers Increase Demand for Hybrid and Diagnostic Auto Repair

Chef LaLa Targets Hotel-Stay Meal Needs After Garden Grove Evacuations

SIX FLAGS FIESTA TEXAS UNLEASHES WEREWOLF GORGE, THE WORLD'S LONGEST FAMILY LAUNCH ROLLER COASTER

Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026

Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet

81% of ChatGPT-Cited Brands Don't Rank on Google: New Study Released

AdvisorVault Adds Social Media Archiving to its Consolidated D3P Service

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other...